Drug firm Lupin on Tuesday said it has received approval from the US health regulator to market its generic Divalproex Sodium extended-release tablets in the American market. The company has received approval from the United States Food and Drug Administration (USFDA) for its Divalproex Sodium extended-release tablets in the strengths of 250 mg and 500 mg, Lupin said in a statement. The company's product is a generic version of AbbVie Inc's Depakote extended-release tablets in the same strengths, it added. As per IQVIA MAT June 2019 data, Divalproex sodium extended-release (ER) tablets USP, 250 mg and 500 mg had annual sales of approximately USD 159 million (over Rs 1,100 crore) in the US, Lupin said.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!